Abbott Neuromodulation Therapies Show Long-Term Reduction in Pain-Related Healthcare Use

Abbott reported positive five-year outcomes from its neuromodulation portfolio, highlighting BurstDR spinal cord stimulation (SCS) and Proclaim dorsal root ganglion (DRG) systems. Data were presented at the 2026 NANS Annual Meeting in Las Vegas.

A retrospective analysis of 16,846 SCS patients showed a 75% reduction in pain-related healthcare visits, with mean visits dropping from 7.5 at baseline to 1.9 after five years. In 834 Proclaim DRG patients, visits decreased by 73%. Among 127 BurstDR patients, 92% preferred the implant over standard tonic stimulation, reporting sustained pain relief and improved physical function.

SCS and DRG systems deliver targeted electrical stimulation to modulate pain signals, allowing personalized therapy and flexibility for patients. Abbott emphasizes that these therapies can reduce healthcare burden, improve long-term outcomes, and strengthen payor and physician confidence.

Abbott continues to expand its neuromodulation portfolio, including the TRANSCEND trial evaluating deep brain stimulation for treatment-resistant depression (primary completion: April 2027).

31-01-2026